Skip to Content
Merck
CN

Key Documents

View All Documentation

EHU051301

MISSION® esiRNA

targeting human WBP2

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CGTCAATAACACCGAGAGCATCCTAATGTCCTATGATCACGTGGAACTCACATTCAATGACATGAAGAACGTGCCAGAAGCCTTCAAAGGGACCAAGAAAGGCACTGTCTACCTTACCCCTTACCGGGTCATCTTTCTGTCCAAGGGCAAGGATGCCATGCAGTCCTTCATGATGCCATTTTATCTCATGAAAGACTGTGAGATCAAGCAGCCCGTATTTGGTGCAAACTACATCAAGGGAACAGTGAAGGCGGAAGCGGGAGGTGGCTGGGAAGGCTCTGCTTCCTACAAGTTGACTTTCACGGCAGGGGGCGCCATTGAGTTCGGACAGCGGATGCTCCAGGTGGCATCTCAAGCCTCCAGAGGTGAAGTCCCCAGTGGAGCCTATGGCTACTCTTACATGCCCAGCGGGGCCTATGTCTATCCCCCGCCAGTCGCCAATGGAATGTACC

Ensembl | human accession no.

ENSG00000132471

NCBI accession no.

NM_012478

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... WBP2(23558)

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Shin-Ae Kang et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(8), 2588-2600 (2018-12-30)
Trastuzumab-based chemotherapy has shown remarkable clinical benefits for patients with HER2-positive breast cancer. However, treatment regimens involving trastuzumab had little or no effect for a subset of patients. Preliminary studies revealed WW-binding protein 2 (WBP2), an oncogenic transcription coactivator, to
Natania S Field et al.
European journal of immunology, 50(10), 1468-1483 (2020-05-28)
To mount an antipathogen response, CD4 T cells must undergo rapid cell proliferation; however, poorly controlled expansion can result in diseases such as autoimmunity. One important regulator of T-cell activity is the E3 ubiquitin ligase Itch. Itch deficient patients suffer

Global Trade Item Number

SKUGTIN
EHU051301-50UG04061828321704
EHU051301-20UG04061828572359